|Bid||205.10 x 800|
|Ask||0.00 x 800|
|Day's Range||208.06 - 213.27|
|52 Week Range||197.47 - 306.08|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||20.26|
|Earnings Date||Apr 27, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||284.73|
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Back in 2016, Bank of America/Merrill Lynch issued a report that compared the performance of growth stocks to value stocks over a 90-year period (1926-2015). The results showed that value stocks were the superior choice (17% annual average return, versus 12.6% for growth stocks), albeit no investors are complaining with annual average returns of 12.6% or 17%. With lending rates at or near historic lows and the Federal Reserve remaining highly accommodative, growth stocks have run circles around value stocks for more than a decade.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET.